by my rough calculations, they will have appx 1000 by the end of...

by my rough calculations, they will have appx 1000 by the end of 2023. depending on how many of these patients end up on full expected dose as opposed to settling at a slightly lower dose due to GI, then this should bring in circa 85-95M in Q4

based on the performance in Q2 and Q3 guidance, i think they projected Q3 based on a constant take up rate without taking into account acceleration of uptake month on month. For mine, that would be the wiser way to provide guidance as it leaves them open to increasing guidance mid Q rather than downgrading or missing guidance. that would be bloody silly at this stage of the rollout.

The share price of Acadia has been interesting. ACAD share price of late could suggest that maybe some investors there think that daybue won't be a blockbuster, but i think it's more about Nuplazid reaching a peak or plateau in growth.